Robert Koblin
Cardiovascular Disease · Beverly Hills, CANPI 1851506083
Payments from drug & device makers
Across 153 payments — averaging $21.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$783
- Daiichi Sankyo Inc.$343
- Novartis$319
- AstraZeneca$229
- Pfizer$214
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$137
- plus $1K from 27 others
What the payments were for
- Food & beverage$3,303100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 44 | $783 |
| Daiichi Sankyo Inc. | 14 | $343 |
| Novartis | 14 | $319 |
| AstraZeneca | 13 | $229 |
| Pfizer | 11 | $214 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $137 |
| Biosense Webster, Inc. | 1 | $125 |
| Boston Scientific | 4 | $116 |
| Regeneron Healthcare Solutions, Inc. | 3 | $109 |
| Lilly USA, LLC | 5 | $104 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $77 |
| Biohaven Pharmaceuticals, Inc. | 3 | $74 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $51 |
| Bardy Diagnostics, Inc. | 2 | $50 |
| AbbVie(2 entities) | 2 | $50 |
| Kowa Pharmaceuticals America, Inc. | 1 | $47 |
| Alnylam Pharmaceuticals Inc. | 2 | $47 |
| Heartflow, Inc. | 2 | $44 |
| Merck | 2 | $43 |
| Sanofi-aventis U.S. LLC | 2 | $40 |
| GSK | 2 | $39 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $32 |
| Viiv Healthcare Company | 1 | $29 |
| Eisai Inc. | 1 | $24 |
| Bayer | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $24 |
| Boehringer Ingelheim | 1 | $24 |
| Esperion Therapeutics, Inc. | 1 | $23 |
| Arbor Pharmaceuticals, Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $17 |
| Janssen Scientific Affairs, LLC | 1 | $17 |
| Philips North America LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Carto 3$125
How this compares
$3,303 in reported general payments places this provider in the 50th percentile of 2,184 cardiovascular disease providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 16 | $9,339 |
| Olmesartan Medoxomil | 13 | $394 |
| Ezetimibe | 12 | $279 |
| Rosuvastatin Calcium | 14 | $132 |
| Losartan Potassium | 12 | $96 |
| Atorvastatin Calcium | 14 | $36 |
| Allopurinol | 11 | $24 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Beverly Hills
- Andriana NikolovaBeverly Hills$980K
- Ronald KarlsbergBeverly Hills$883K
- Bruce SamuelsBeverly Hills$598K
- Charles SwerdlowBeverly Hills$562K
- Ted LoveHillsborough$102.8M
- Matthew BudoffTorrance$11.3M
- Lori DanielsSan Diego$10.2M
- Paul KurthSanta Barbara$6.1M
- Michael BlumSan Francisco$5.5M
- Tony ChouSan Francisco$5.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.